Literature DB >> 25162889

Transmission of MERS-coronavirus in household contacts.

Christian Drosten1, Benjamin Meyer, Marcel A Müller, Victor M Corman, Malak Al-Masri, Raheela Hossain, Hosam Madani, Andrea Sieberg, Berend Jan Bosch, Erik Lattwein, Raafat F Alhakeem, Abdullah M Assiri, Waleed Hajomar, Ali M Albarrak, Jaffar A Al-Tawfiq, Alimuddin I Zumla, Ziad A Memish.   

Abstract

BACKGROUND: Strategies to contain the Middle East respiratory syndrome coronavirus (MERS-CoV) depend on knowledge of the rate of human-to-human transmission, including subclinical infections. A lack of serologic tools has hindered targeted studies of transmission.
METHODS: We studied 26 index patients with MERS-CoV infection and their 280 household contacts. The median time from the onset of symptoms in index patients to the latest blood sampling in contact patients was 17.5 days (range, 5 to 216; mean, 34.4). Probable cases of secondary transmission were identified on the basis of reactivity in two reverse-transcriptase-polymerase-chain-reaction (RT-PCR) assays with independent RNA extraction from throat swabs or reactivity on enzyme-linked immunosorbent assay against MERS-CoV S1 antigen, supported by reactivity on recombinant S-protein immunofluorescence and demonstration of neutralization of more than 50% of the infectious virus seed dose on plaque-reduction neutralization testing.
RESULTS: Among the 280 household contacts of the 26 index patients, there were 12 probable cases of secondary transmission (4%; 95% confidence interval, 2 to 7). Of these cases, 7 were identified by means of RT-PCR, all in samples obtained within 14 days after the onset of symptoms in index patients, and 5 were identified by means of serologic analysis, all in samples obtained 13 days or more after symptom onset in index patients. Probable cases of secondary transmission occurred in 6 of 26 clusters (23%). Serologic results in contacts who were sampled 13 days or more after exposure were similar to overall study results for combined RT-PCR and serologic testing.
CONCLUSIONS: The rate of secondary transmission among household contacts of patients with MERS-CoV infection has been approximately 5%. Our data provide insight into the rate of subclinical transmission of MERS-CoV in the home.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25162889     DOI: 10.1056/NEJMoa1405858

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  193 in total

1.  Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses.

Authors:  Jingxian Zhao; Abeer N Alshukairi; Salim A Baharoon; Waleed A Ahmed; Ahmad A Bokhari; Atef M Nehdi; Laila A Layqah; Mohammed G Alghamdi; Manal M Al Gethamy; Ashraf M Dada; Imran Khalid; Mohamad Boujelal; Sameera M Al Johani; Leatrice Vogel; Kanta Subbarao; Ashutosh Mangalam; Chaorong Wu; Patrick Ten Eyck; Stanley Perlman; Jincun Zhao
Journal:  Sci Immunol       Date:  2017-08-04

Review 2.  Certainty of success: three critical parameters in coronavirus vaccine development.

Authors:  David C Kaslow
Journal:  NPJ Vaccines       Date:  2020-05-25       Impact factor: 7.344

3.  Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection.

Authors:  Jincun Zhao; Ranawaka A P M Perera; Ghazi Kayali; David Meyerholz; Stanley Perlman; Malik Peiris
Journal:  J Virol       Date:  2015-03-18       Impact factor: 5.103

Review 4.  Middle East Respiratory Syndrome Coronavirus and Children.

Authors:  Michael Bartenfeld; Stephanie Griese; Timothy Uyeki; Susan I Gerber; Georgina Peacock
Journal:  Clin Pediatr (Phila)       Date:  2016-11-23       Impact factor: 1.168

Review 5.  Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease.

Authors:  Jasper F W Chan; Susanna K P Lau; Kelvin K W To; Vincent C C Cheng; Patrick C Y Woo; Kwok-Yung Yuen
Journal:  Clin Microbiol Rev       Date:  2015-04       Impact factor: 26.132

Review 6.  MERS coronavirus: diagnostics, epidemiology and transmission.

Authors:  Ian M Mackay; Katherine E Arden
Journal:  Virol J       Date:  2015-12-22       Impact factor: 4.099

7.  A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.

Authors:  Anna H Malczyk; Alexandra Kupke; Steffen Prüfer; Vivian A Scheuplein; Stefan Hutzler; Dorothea Kreuz; Tim Beissert; Stefanie Bauer; Stefanie Hubich-Rau; Christiane Tondera; Hosam Shams Eldin; Jörg Schmidt; Júlia Vergara-Alert; Yasemin Süzer; Janna Seifried; Kay-Martin Hanschmann; Ulrich Kalinke; Susanne Herold; Ugur Sahin; Klaus Cichutek; Zoe Waibler; Markus Eickmann; Stephan Becker; Michael D Mühlebach
Journal:  J Virol       Date:  2015-09-09       Impact factor: 5.103

Review 8.  Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus.

Authors:  Anthony R Fehr; Rudragouda Channappanavar; Stanley Perlman
Journal:  Annu Rev Med       Date:  2016-08-26       Impact factor: 13.739

9.  Differential Expression of the Middle East Respiratory Syndrome Coronavirus Receptor in the Upper Respiratory Tracts of Humans and Dromedary Camels.

Authors:  W Widagdo; V Stalin Raj; Debby Schipper; Kimberley Kolijn; Geert J L H van Leenders; Berend J Bosch; Albert Bensaid; Joaquim Segalés; Wolfgang Baumgärtner; Albert D M E Osterhaus; Marion P Koopmans; Judith M A van den Brand; Bart L Haagmans
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

10.  Transgene expression in the genome of Middle East respiratory syndrome coronavirus based on a novel reverse genetics system utilizing Red-mediated recombination cloning.

Authors:  Doreen Muth; Benjamin Meyer; Daniela Niemeyer; Simon Schroeder; Nikolaus Osterrieder; Marcel Alexander Müller; Christian Drosten
Journal:  J Gen Virol       Date:  2017-10       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.